In July 2026, OKYO Pharma’s Chief Scientific Officer increased his equity stake, signaling management confidence amid ongoing clinical development of Urcosimod for neuropathic corneal pain. Recent FDA feedback endorsing the NEPTUNE trial design reduces regulatory uncertainty and supports streamlined progression. The company remains pre-revenue, funding operations through equity and convertible loans, with R&D and administrative costs reflecting typical early-stage biotech burn. While operating in a niche ophthalmic indication with some IP protection, OKYO faces standard industry risks including clinical execution, funding demands, and regulatory challenges.